Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
NCT03965494 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · EARLY_PHASE1 · terminated · last registry update 2024-02-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer - official close date is 10/31/23” | – | Registry record, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AXL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-29Results posted on the registry: BerGenBio ASA, Bemcentinib (NCT06469138)
- 2025-01-14Results posted on the registry: Astellas Pharma Inc, Gilteritinib + Cytarabine (NCT03182244)
- 2024-12-19Results posted on the registry: BerGenBio ASA, Bemcentinib + Cytarabine (NCT02488408)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-11-27Also stopped (terminated): Astellas Pharma Global Development, Inc., Gilteritinib + Erlotinib (NCT02495233)
- 2024-10-16Results posted on the registry: Astellas Pharma Inc, Gilteritinib + Idarubicin (NCT02310321)
- 2024-10-16Results posted on the registry: BerGenBio ASA, Bemcentinib (NCT04890509)
- 2024-09-19Results posted on the registry: Astellas Pharma Global Development, Inc., gilteritinib + Placebo (NCT02997202)
- 2024-08-07Results posted on the registry: Kronos Bio, Lanraplenib + Gilteritinib (NCT05028751)
- 2024-08-07Also stopped (terminated): Kronos Bio, Lanraplenib + Gilteritinib (NCT05028751)
- 2024-05-31Also stopped (terminated): Celgene, CC-90009 + Venetoclax (NCT04336982)
- 2023-11-09Results posted on the registry: University of Texas Southwestern Medical Center, Bemcentinib + Nab-paclitaxel (NCT03649321)
- 2023-11-09Also stopped (terminated): University of Texas Southwestern Medical Center, Bemcentinib + Nab-paclitaxel (NCT03649321)
- 2023-04-25Also stopped (withdrawn): Ayman H Qasrawi, Gilteritinib 40 MG Oral Tablet + Cladribine (NCT05330377)
- 2023-03-02Also stopped (terminated): Jiangsu Alphamab Biopharmaceuticals Co., Ltd, KN046 + KN046 (NCT03838848)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision